Study of alpha-synuclein brain disease in patients and healthy people
Part of Brain & nervous system clinical trials.
This study follows people with a primary alpha-synuclein diagnosis and compares them with healthy controls. It aims to better understand this condition and may help researchers design better future tests and treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor’s clinical diagnosis of primary alpha-synuclein disease (alpha-synucleinopathy)
- If you are a healthy control, you must be a person without this disease
- You must not have secondary alpha-synuclein disease that can’t be ruled out
- You must not have other neurological (brain/nervous system) disorders
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new imaging scan (18F-CP6A PET) to detect a protein called alpha-synuclein in the brain. If you have Parkinson's disease, multiple system atrophy, or Lewy body dementia, or if you are a healthy volunteer, this scan may help doctors better understand these conditions.
This study examines changes in alpha-synuclein, a protein linked to Parkinson's, to better understand how the disease progresses. It may help researchers learn more about Parkinson's and improve future care.
This study helps people understand a protein called alpha-synuclein that may be related to memory problems and movement disorders. Researchers will either test your spinal fluid or skin to look for this protein, then discuss the results with you and measure how you're doing over time.
This study looks for changes in a protein called alpha-synuclein in people who may be in the early “prodromal” stage before Parkinson’s symptoms fully appear. It may help researchers find early markers and understand who is more likely to develop Parkinson’s disease.
This study collects health information from people with neurodegenerative diseases, some family members, and healthy controls to help researchers better understand these conditions. It may help future diagnosis and research, and participation may include noninvasive checks and other procedures depending on your situation.
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
Hear when a new α-synucleinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.